Coronavirus disease 2019 (Covid-19): Do angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers have a biphasic effect?

Journal of the American Heart Association

Volumn 9, Issue 7, 2020, Pages

  Sommerstein, Rami ^a   Kochen, Michael M ^b   Messerli, Franz H ^a,c,d   Gräni, Christoph ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ACE2; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Coronavirus disease 2019; Epidemiology; Infectious diseases

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK FACTOR; CEREBROVASCULAR DISEASE; CHINA; CLINICAL OUTCOME; COMORBIDITY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; EVIDENCE BASED PRACTICE; GENDER; GENE EXPRESSION; HEART PROTECTION; HUMAN; HYPERTENSION; INFECTION RISK; ISCHEMIC HEART DISEASE; MORTALITY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT DURATION; UPREGULATION; VIRUS ENTRY; VIRUS REPLICATION; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; DISEASE NOTIFICATION; METABOLISM; PANDEMIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VIRUS PNEUMONIA;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BETACORONAVIRUS; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONAVIRUS INFECTIONS; DISEASE NOTIFICATION; HUMANS; PANDEMICS; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85082732153     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.120.016509     Document Type: Article

References (26)

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;pii: S1473-3099(20)30120-1. DOI: 10.1016/S1473-3099(20)30120-1. [Epub ahead of print].
3. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Wkly. 2020;2:113–122.
4. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71:1474–1482.
5. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. 2020.01.31.929042. Posted January 31, 2020.
6. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme in-hibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–2610.
7. Sommerstein R, Gräni C. Rapid response: re: preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ 2020. Available at: http://www.bmj.com/content/368/bmj.m810/rr-2. Accessed March 20, 2020.
8. HFSA/ACC/AHA statement addresses concerns re: using RAAS an-tagonists in COVID-19. March 17, 2020. Available at: https://www.acc. org/latest-in-cardi​ology/​artic​les/2020/03/17/08/59/hfsa-acc-aha-state​ ment-addre​sses-conce​rns-re-using-raas-antag​onists-in-covid-19. Accessed March 20, 2020.
9. European Societies of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. March 13, 2020. Available at: https://www.escar​dio. org/Counc​ils/Counc​il-on-Hyper​tensi​on-(CHT)/News/posit​ion-state​ ment-of-the-esc-counc​il-on-hyper​tensi​on-on-ace-inhib​itors-and-ang. Accessed March 20, 2020.
10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; DOI: 10.1001/jama.2020.1585. [Epub ahead of print].
12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
13. Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality—preliminary results. medRxiv. 2020. 2020.02.24.20027268. Posted: February 25, 2020.
14. Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005–2016. Hypertension. 2020;75:973–981.
15. ECDC. Case definition and European surveillance for COVID-19, as of 2 March 2020. Available at: https://www.ecdc.europa.eu/en/case-definition-and-europ​ean-surve​illan​ce-human-infec​tion-novel-coron​avirus-2019-ncov. Accessed March 20, 2020.
16. Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavi-rus 2 infection. J Am Heart Assoc. 2020;9:e016219. DOI: 10.1161/JAHA.120.016219.
17. Fernández-Atucha A, Izagirre A, Fraile-Bermúdez AB, Kortajarena M, Larrinaga G, Martinez-Lage P, Echevarría E, Gil J. Sex differences in the aging pattern of renin-angiotensin system serum peptidases. Biol Sex Differ. 2017;8:5.
18. Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural re-modelling. Europace. 2017;19:1280–1287.
19. Chappel MC, Ferrario CM. ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7). Kidney Int. 2006;70:8–10.
20. Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol. 2010;298:F1297–F1305.
21. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005;289:H1013–H1019.
22. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, Hamie QM, Meier CF, Hunziker S, Forras-Kaufmann Z, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47:693–705.
23. Uri K, Fagyas M, Manyine Siket I, Kertesz A, Csanadi Z, Sandorfi G, Clemens M, Fedor R, Papp Z, Édes I. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a bio-marker of systolic dysfunction in human hypertension and heart failure. PLoS One. 2014;9:e87845.
24. Uri K, Fagyas M, Kertesz A, Borbely A, Jenei C, Bene O, Csanádi Z, Paulus WJ, Édes I, Papp Z, et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst. 2016;17:1470320316668435.
25. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879.
26. Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P, Wang K, Han L, Duan Y, Zhao Z, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016;6:19840.